Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 3,619 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes-Mellitus, Non-Insulin Dependent Clear all
Completed Phase 1 Interventional

A Safety Study of ARRY-403 in Patients With Type 2 Diabetes

NCT00859755
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ARRY-403, glucokinase activator; oral, Placebo; oral
Drug
Lead sponsor
Array BioPharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Effect of JNJ-28431754 (Canagliflozin) on Post-Meal Glucose in Patients With Type 2 Diabetes Mellitus

NCT01381887
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, Canagliflozin 300mg/Placebo, Canagliflozin 300mg/Canagliflozin 150mg, Canagliflozin 300mg
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
25 Years to 70 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
5
States / cities
Chula Vista, California • Miramar, Florida • Cincinnati, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2013 · Synced Oct 8, 2026, 5:51 PM EDT
Completed No phase listed Observational

Cross-Sectional and Longitudinal Studies of "Pre-Diabetes" in the Pima Indians

NCT00340132
View directory record Official record
Conditions
Weight Gain, Overweight, Insulin Resistance, Obesity, Diabetes Mellitus, Type 2
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 55 Years
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1983
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Enhancing mHealth Technology to Activate Chronic Care Patients

NCT02949037
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Mobile Health Care Environment (MHCE)
Other
Lead sponsor
Clemson University
Other
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Nellis Air Force Base, Nevada • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Aug 6, 2020 · Synced Oct 8, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Mitochondrial Methylation in Type 2 Diabetes

NCT04126551
View directory record Official record
Conditions
Overweight, Obesity, Diabetes Mellitus, Type 2, Insulin Resistance
Interventions
Methylation status
Other
Lead sponsor
University of Arizona
Other
Eligibility
21 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.

NCT00570739
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
Interventions
Metformin HCl and Colesevelam Placebo, Metformin HCl tablets and Colesevelam tablets, Colesevelam placebo, Colesevelam
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 79 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
17
States / cities
Birmingham, Alabama • Los Gatos, California • Tarzana, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Circuit Training and Motivational Interviewing to Reduce Type 2 Diabetes in Youth

NCT00693511
View directory record Official record
Conditions
Obesity and Type 2 Diabetes
Interventions
Circuit Training, Circuit training + motivational interviewing
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
14 Years to 18 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Effect of Repaglinide and Metformin Combination Tablet or Rosiglitazone and Metformin in Fixed Dose Combination on Blood Glucose Control in Patients With Type 2 Diabetes

NCT00399711
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide and metformin combination tablet, rosiglitazone and metformin combination tablet
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
102
States / cities
Vestavia Hills, Alabama • Glendale, Arizona • Mesa, Arizona + 90 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2017 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study to See How Much Semaglutide and SNAC is in the Milk of Healthy, Breastfeeding Women Taking Semaglutide Tablets

NCT04817644
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Oral semaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of INCB013739 Plus Metformin Compared to Metformin Alone on Glycemic Control in Type 2 Diabetics

NCT00698230
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
INCB013739, Placebo comparator matching INCB013739, Metformin
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
62
States / cities
Birmingham, Alabama • Artesia, California • Calabasas, California + 54 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 8, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional

Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

NCT06681428
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
Interventions
Allograft
Other
Lead sponsor
Tides Medical
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Fresno, California • Los Angeles, California • Vista, California + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 8, 2026, 5:51 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes

NCT01455909
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650 60 mcg/day, sitagliptin
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinic to Community Connections - Broader Distribution

NCT04474795
View directory record Official record
Conditions
Gestational Diabetes, Gestational Diabetes Mellitus in Pregnancy
Interventions
Staff -Educational training
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 27, 2023 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 2 Interventional

Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM

NCT01658501
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
50 mg PB1023, 70 mg PB1023, 100 mg PB1023, Placebo (0.9% Sodium Chloride), Victoza®, Diet and Exercise, Metformin, Sulfonylurea, Metformin and Sulfonylurea
Drug · Other
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
593 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
93
States / cities
Anniston, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Oct 8, 2026, 5:51 PM EDT
Completed No phase listed Observational

Role of CGMS Usage in Predicting Risk for Hypoglycemia

NCT03481530
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Hypoglycemia
Interventions
Continuing Glucose Monitor System
Device
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Ranolazine, Placebo, Glimepiride, Diet, Exercise
Drug · Behavioral
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
431 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
46
States / cities
Mesa, Arizona • Tucson, Arizona • Pine Bluff, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

MapTrek to Increase Activity Among Patients at Risk for Type 2 Diabetes

NCT03193229
View directory record Official record
Conditions
Pre Diabetes, Obesity
Interventions
MapTrek, Fitbit
Behavioral · Device
Lead sponsor
Philip Polgreen
Other
Eligibility
21 Years to 80 Years
Enrollment
430 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Coralville, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 8, 2026, 5:51 PM EDT
Active, not recruiting Phase 1 Interventional

Evaluation of Basal Insulin Initialization and Titration in People With Type 2 Diabetes Wearing a Dexcom G6 Sensor

NCT07681375
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Basal insulin, Dexcom Continuous Glucose Monitoring (CGM)
Drug · Device
Lead sponsor
DexCom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 8, 2026, 5:51 PM EDT
Terminated Phase 4 Interventional Results available

The LANCET Trial: A Trial of Long-acting Insulin Injection to Reduce C-reactive Protein in Patients With Type 2 Diabetes

NCT00366301
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine injection, metformin, Placebo pill
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 79 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 25, 2010 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Bingocize: A Novel Mobile Application for Older Adult Health

NCT03629912
View directory record Official record
Conditions
Activities of Daily Living, Accidental Fall, Sarcopenia, Arteriosclerosis, Diabetes Mellitus, Type 2, Hypertension, Cognitive Decline, Executive Function, Cognitive Aging
Interventions
Socially-Based Exercise Intervention for Older Adults
Behavioral
Lead sponsor
Western Kentucky University
Other
Eligibility
60 Years to 85 Years
Enrollment
241 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
4
States / cities
Dixon, Kentucky • Henderson, Tennessee • Johnson City, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 8, 2026, 5:51 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sedentary Behavior in Older Women With and Without Type 2 Diabetes

NCT04262128
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Healthy
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 75 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2025 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Manual Medicine or Cognitive Behavioral Therapy With Chronic Uncontrolled Diabetes

NCT02971865
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
CBT/CMT, Control group traditional primary care
Behavioral · Other
Lead sponsor
Community Wellness Center, West Linn, OR
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
West Linn, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 23, 2016 · Synced Oct 8, 2026, 5:51 PM EDT
Completed No phase listed Observational

Economic Outcomes of EQW (Exenatide Once Weekly) vs. IG (Insulin Glargine) in T2D Patients Who Are New to Injectable Therapy

NCT02843399
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 99 Years
Enrollment
15,498 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 8, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

NCT01473953
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Healthy
Interventions
liraglutide-depot, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 8, 2026, 5:51 PM EDT